Oregovomab: an investigational agent for the treatment of advanced ovarian cancer-Reference-Cited by-同舟云学术

Oregovomab: an investigational agent for the treatment of advanced ovarian cancer

Published:2021-01-11 Issue:2 Volume:30 Page:103-110
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Pietragalla Antonella¹^ORCID,Duranti Simona¹^ORCID,Daniele Gennaro¹^ORCID,Nero Camilla²^ORCID,Ciccarone Francesca²^ORCID,Lorusso Domenica¹³^ORCID,Fagotti Anna²³^ORCID,Scambia Giovanni¹³^ORCID

Affiliation:

1. Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

2. Division of Gynaecologic Oncology, Department Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

3. Department of Life Science and Public Health, Università Cattolica Del Sacro Cuore, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2021.1868436

Reference46 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

3. CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer

4. Recent progress in the diagnosis and treatment of ovarian cancer

5. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico Identification of MHC Displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-09

2. Progress in the treatment of malignant ascites;Critical Reviews in Oncology/Hematology;2024-02

3. Targeting the immune microenvironment for ovarian cancer therapy;Frontiers in Immunology;2023-12-18

4. Insilico Identification of MHC displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct;2023-02-15

5. The efficacy of TP chemotherapy combined with karelizumab on the postoperative clinical status of patients with advanced ovarian cancer;European Journal of Gynaecological Oncology;2023